Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT01360853. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The question being asked in this study is: Will patients with advanced pancreatic cancer live significantly longer if they are treated with a combination of Gemcitabine and ON 01910.Na than if they are treated with Gemcitabine alone? There are two parts to this study. In the first part of the study, patients with metastatic pancreatic cancer who have received no prior chemotherapy for this disease will be assigned by chance either to the group that will be treated with both Gemcitabine and ON 01910.Na (about 100 patients will be in this group) or, to the group that will be treated with Gemcitabine only (about 50 patients will be in this group). How long patients survive in the 2 groups will be compared. If it looks like there is no difference between the groups, the study will stop. If it looks like patients in the group that were treated with both Gemcitabine and ON 01910.Na survive longer, the study will continue into a second part where more patients will be treated in order to confirm and better understand the findings of the first part of the study.
Study identification
- NCT ID
- NCT01360853
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2011 (Type not available)
- Primary completion
- Jun 2015 (Actual)
- Completion
- Dec 2015 (Actual)
- Last update posted
- Aug 4, 2016
2011 – 2015
United States locations
- U.S. sites
- 30
- U.S. states
- 18
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Moores Cancer Center | La Jolla | California | 92037 | — |
| Desert Comprehensive Cancer Center | Palm Springs | California | 92262 | — |
| Pacific Cancer Care | Salinas | California | 93901 | — |
| Premiere Oncology | Santa Monica | California | 90404 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Kaiser Permanente Colorado | Denver | Colorado | 80205 | — |
| Poudre Valley Cancer Center of the Rockies | Fort Collins | Colorado | 80528 | — |
| Yale Cancer Center | New Haven | Connecticut | 06519 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| University of Hawaii Cancer Center | Honolulu | Hawaii | 96813 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| UMASS Medical School | Worcester | Massachusetts | 01655 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Billings Clinic Cancer Center | Billings | Montana | 59101 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| New York University Langone Medical Center | New York | New York | 10016 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| University of North Carolina Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Cone Health Cancer Center | Greensboro | North Carolina | 27403 | — |
| Hendersonville Hematology and Oncology at Pardee | Hendersonville | North Carolina | 28971 | — |
| Rex Cancer Center UNC Healthcare | Raleigh | North Carolina | 27607 | — |
| St. Alexis Medical Center-Mid Dakota Clinic PC | Bismarck | North Dakota | 58501 | — |
| University of Cincinnati Cancer Center | Cincinnati | Ohio | 45219 | — |
| Kaiser Permanente NW | Portland | Oregon | 97227 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Medical University of South Carolina - Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| McLeod Regional Medical Center | Florence | South Carolina | 29506 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01360853, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2016 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01360853 live on ClinicalTrials.gov.